XTX Topco Ltd Decreases Stock Position in REGENXBIO Inc. (NASDAQ:RGNX)

Key Points

• XTX Topco Ltd reduced its stake in REGENXBIO Inc. by 66.7% during the 1st quarter, now holding approximately 0.07% of the company valued at $257,000.
• Analysts have varied opinions on REGENXBIO's stock, with Goldman Sachs lowering its price target to $12.00 while Chardan Capital maintains a "buy" rating with a target of $52.00.
• REGENXBIO reported a significant loss, missing earnings estimates by $0.25, with a revenue of $21.36 million compared to expectations of $40.87 million.

XTX Topco Ltd lowered its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 66.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,953 shares of the biotechnology company's stock after selling 72,167 shares during the quarter. XTX Topco Ltd owned approximately 0.07% of REGENXBIO worth $257,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Janney Montgomery Scott LLC purchased a new position in REGENXBIO during the first quarter worth approximately $484,000. Wealth Enhancement Advisory Services LLC purchased a new position in REGENXBIO during the first quarter worth approximately $123,000. Price T Rowe Associates Inc. MD boosted its position in REGENXBIO by 9.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock worth $185,000 after purchasing an additional 1,982 shares in the last quarter. BNP Paribas Financial Markets boosted its position in REGENXBIO by 370.1% during the fourth quarter. BNP Paribas Financial Markets now owns 96,093 shares of the biotechnology company's stock worth $743,000 after purchasing an additional 75,652 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in REGENXBIO by 34.0% during the fourth quarter. Wells Fargo & Company MN now owns 48,437 shares of the biotechnology company's stock worth $374,000 after purchasing an additional 12,285 shares in the last quarter. Hedge funds and other institutional investors own 88.08% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on RGNX shares. Wall Street Zen downgraded REGENXBIO from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 9th. Barclays decreased their target price on REGENXBIO from $50.00 to $37.00 and set an "overweight" rating on the stock in a research report on Friday, August 8th. Chardan Capital restated a "buy" rating and issued a $52.00 target price on shares of REGENXBIO in a research report on Friday, August 8th. Finally, Royal Bank Of Canada decreased their target price on REGENXBIO from $21.00 to $17.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $28.38.

REGENXBIO Price Performance

REGENXBIO stock traded down $0.24 during trading on Friday, reaching $8.82. 660,862 shares of the company were exchanged, compared to its average volume of 696,637. REGENXBIO Inc. has a 52-week low of $5.03 and a 52-week high of $13.48. The company has a market capitalization of $445.50 million, a P/E ratio of -2.56 and a beta of 1.11. The stock's 50 day simple moving average is $8.67 and its two-hundred day simple moving average is $8.06.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts' consensus estimates of ($1.13) by ($0.25). REGENXBIO had a negative return on equity of 66.95% and a negative net margin of 112.70%. The company had revenue of $21.36 million for the quarter, compared to analysts' expectations of $40.87 million. As a group, equities analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.